McCoyt wants to build a platform-based innovative drug development company that develops First-in-Class and Best-in-class varieties
Recently, “Mccoot (Shaanxi Mactech Technology Co., Ltd.) announced the completion of the Pre-A round of financing of 115 million yuan. This round of financing was led by Arctic Light Ventures, and four institutions including Tianshili Capital Holdings, Detong Capital and Junying Growth Fund. The financing will be mainly used to promote the clinical research of multiple varieties of the company’s “bispecific” peptide new molecular entity drug pipeline.
Founded in 2007, “Mccoot” is a new biomolecule drug developer based in China, covering the development of new biomolecules of “bispecific” peptides, focusing on cardiovascular and cerebrovascular diseases, metabolic diseases, Three major areas of neurological systemic diseases.
First, what is a peptide drug?
Polypeptide refers to a class of compounds composed of amino acids linked by peptide bonds, and is widely used in many fields such as medicine, food, health care products, cosmetics, biological materials, and biological pesticides. According to the Guolian Securities Research Report, peptide drugs possess some advantages of chemical drugs and protein drugs: like small molecules of chemical drugs, they have good stability, high purity, and weak immunogenicity. They also have the biological activity of protein drugs. Strong specificity.
According to reports, the core technology of “McCoate” focuses on the design and formulation of peptide drugs, especially dual-target or multi-target peptide technology. Compared to a single polypeptide, this technology maximizes the benefits of biological activity, minimizes side effects, and provides a more balanced pharmacokinetic profile through simultaneous activation of different signaling mechanisms.
McCoate’s part of the R&D product pipeline layout
At present, the “McCoate” product line includes a new molecular entity drug development platform for bispecific peptides, a central nervous system drug research platform that crosses the blood-brain barrier, and a high-end formulation research platform. At the same time, “Mccoot” has a number of bifunctional peptide varieties in development. For example, “Mccoot” has two products in the cardiovascular and cerebrovascular field that have entered the clinical research stage, in which MT-1002 bifunctional peptide is in clinical phase I.